Sectors

TVGN
Tevogen Bio Holdings Inc.
6.98
2 x 4.83
2 x 8.30
bid
ask
+
0.09
1.31%
2 @ 04:00 PM
7.31 +0.33 (4.73%)
Ytd-57.82%
1y-84.66%
6.80
day range
6.98
3.64
52 week range
49.50
Open6.82Prev Close6.89Low6.80High6.98Mkt Cap45.45M
Vol8.55KAvg Vol17.53KEPS-6.29P/EN/AForward P/EN/A
Beta0.18Short Ratio0.09Inst. Own3.82%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning11-1350-d Avg6.29200-d Avg11.041yr Est4.20

TVGN News

benzinga.com
Tevogen To Operate Under Tevogen Inc. Name, Effective July 30

Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced th

12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session

Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 159.6% to $7.68 during Monday&

benzinga.com
Tevogen Creates Healthcare Services Initiative Led By VP Of Strategic Initiatives William Keane On I

Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced the

12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session

benzinga.com
Tevogen Bio Holdings Q1 EPS $(1.61) Beats $(2.50) Estimate

Tevogen Bio Holdings (NASDAQ:TVGN) reported quarterly losses of $(1.61) per share which beat the ana

12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session

12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session

benzinga.com
Tevogen Enters $3M Private Placement PIPE Financing At $8.00/Prefunded Warrant, Issuing 375K Warrant

Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced tha

12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session

benzinga.com
Tevogen Bio Eyes Acquisition Of Global CRO To Add $20M+ Revenue And Fuel Growth Across Oncology, Rar

Potential transaction expected to add $20M+ in revenue and support double-digit growth, further stre

benzinga.com
Tevogen Bio Regains Nasdaq Compliance

Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) received written no

benzinga.com
Tevogen Reports Advanced Performance For Its AI Platform; Recent Testing Of PredicTcell Model Shows

Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced per

BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session
benzinga.com
BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Sessi

U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-

benzinga.com
Tevogen Names Leadership Team For Diversified Growth Strategy Targeting Additional $50M In Annual Re

Leadership Designations:Digital Health: Arpita Patel and Wojtek StobinskiGenerics: Sadiq Khan and Da

Tevogen Bio Explores Buyout To Boost Generics Platform
benzinga.com
Tevogen Bio Explores Buyout To Boost Generics Platform

Tevogen stock swings after Apozeal acquisition talks and a 50-for-1 reverse split as TVGN trades nea

Marvell Technology, Day One Biopharmaceuticals, Samsara And Other Big Stocks Moving Higher On Friday
benzinga.com
Marvell Technology, Day One Biopharmaceuticals, Samsara And Other Big Stocks Moving Higher On Friday

Dow Jones falls 500 points on Friday, Marvell Technology shares jump 18.4%, other stocks recording g

benzinga.com
Tevogen Bio Holdings Signs Letter Of Intent To Evaluate Potential Acquisition Of Apozeal Pharmaceuti

If consummated, the potential acquisition of Apozeal could provide Tevogen with an established gener

benzinga.com
UPDATE: Tevogen Bio Holdings Approves 1-For-50 Reverse Stock Split Effective March 6, 2026

Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced tha

benzinga.com
D. Boral Capital Maintains Buy on Tevogen Bio Holdings, Lowers Price Target to $2

D. Boral Capital analyst Jason Kolbert maintains Tevogen Bio Holdings (NASDAQ:TVGN) with a Buy an

benzinga.com
Tevogen Strikes Letter Of Intent To Mull Potential Takeover Of Unnamed Contract Research Organizatio

Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced tha

benzinga.com
Tevogen Signs Non-Exclusive, Non-Binding LOI To Evaluate Potential Transaction With Sciometrix To Au

Tevogen ("Tevogen Bio Holdings Inc.") (NASDAQ:TVGN) today announced that it has entered into

benzinga.com
Tevogen Evaluates Potential One-Time Special Cash Dividend, Subject To Future Financial Milestones

Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced tha

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session

benzinga.com
Tevogen Reports 2025 Milestones, Expands ExacTcell Platform And Multi-Indication CTL Pipeline; Advan

Jan. 12, 2026, San Francisco. Issued from the J.P. Morgan Healthcare ConferenceWARREN, N.J., Jan. 12

benzinga.com
Tevogen Provided Updates At J.P. Morgan Healthcare Conference

Pipeline Expansion Across Multiple Indications:Building on its SARS-CoV-2 proof-of-concept clinical

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Why Heartbeam Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Heartbeam Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket

benzinga.com
D. Boral Capital Maintains Buy on Tevogen Bio Holdings, Lowers Price Target to $5

D. Boral Capital analyst Jason Kolbert maintains Tevogen Bio Holdings (NASDAQ:TVGN) with a Buy an

benzinga.com
Tevogen Expands COVID-19 T Cell Therapy Reach With Multi-HLA Targeting, Expanding Patient Eligibilit

This milestone expands patient eligibility through multi-HLA targetingBuilds on completed TVGN 489 t

benzinga.com
Tevogen Clarifies GAAP-Reported Deficit, Plans Non-GAAP Metrics Disclosure Post Q3 2025 Filing

Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today issued a sta

benzinga.com
Tevogen Intends To Collaborate With Government Initiatives, Long COVID Patient Organizations, And Ma

Company intends to collaborate with government initiatives, Long COVID patient organizations, and ma

benzinga.com
Tevogen Bio Announces Progress On Its PredicTcell Platform Which Uses Advanced Machine Learning And

Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ: TVGN), today announced s

benzinga.com
Tevogen Highlights Potential Of Precision T Cell Therapy TVGN 489 To Target Persistent Viral Reservo

Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today highlights e

benzinga.com
Tevogen Bio Estimates TVGN 116 Cumulative 5-Yr Top-Line Revenue To Be ~$6.5B; Risk Adjusted Net Pres

Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ: TVGN), today shared asse

benzinga.com
Tevogen Projects $3.5B Revenue For EBV-Targeting Therapy TVGN 930, With rNPV Exceeding $250M In U.S.

The risk adjusted Net Present Value (rNPV) for TVGN 930 is estimated to exceed ~$250 million in the

benzinga.com
D. Boral Capital Maintains Buy on Tevogen Bio Holdings, Maintains $10 Price Target

D. Boral Capital analyst Jason Kolbert maintains Tevogen Bio Holdings (NASDAQ:TVGN) with a Buy an

benzinga.com
Tevogen Highlights Clinical Data For TVGN 489, A T Cell Therapy Targeting COVID-19 In Immunocompromi

Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today highlighted

benzinga.com
Tevogen Reports 24% Rise In Institutional Ownership In Q2 2025, Led By Morgan Stanley And BlackRock

Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced an

benzinga.com
Tevogen Bio Secures Up To $50M In Financing Following $94.9M Liability Elimination; Formalizes Agree

Includes $36 million line of credit and potential $14 million private placementWARREN, N.J., Aug. 19

benzinga.com
D. Boral Capital Maintains Buy on Tevogen Bio Holdings, Maintains $10 Price Target

D. Boral Capital analyst Jason Kolbert maintains Tevogen Bio Holdings (NASDAQ:TVGN) with a Buy an

benzinga.com
Tevogen Bio Highlights Undervalued Intangible Assets, Citing Proprietary IP, AI Platforms And 74% In

Tevogen Bio Holdings Inc. ("Tevogen" or the "Company") (NASDAQ:TVGN), today issued t

benzinga.com
UPDATE: Tevogen Bio Forecasts $1B Launch-Year Revenue, Sees $18B–$22B Over 5 Years, Driven By PASC T

Treatment of a subgroup of patients with post-acute sequelae of SARS-CoV-2.Forecast adds to Tevogen

benzinga.com
Tevogen Bio Announces $1B Revenue Forecast For The Launch Year Of Its Oncology Pipeline, With A 5-ye

Tevogen Bio ("Tevogen" or "Tevogen Bio Holdings Inc.") (NASDAQ:TVGN), a clinical-sta

benzinga.com
Tevogen Reports Institutional Ownership Jumps 60% In Q1; Vanguard And BlackRock Boost Holdings By 15

Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced an

benzinga.com
D. Boral Capital Maintains Buy on Tevogen Bio Holdings, Maintains $10 Price Target

D. Boral Capital analyst Jason Kolbert maintains Tevogen Bio Holdings (NASDAQ:TVGN) with a Buy an

benzinga.com
Tevogen's Tevogen.AI Expands Collaboration With Microsoft And Databricks, To Build The Beta Version

WARREN, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or &#34

benzinga.com
D. Boral Capital Maintains Buy on Tevogen Bio Holdings, Maintains $10 Price Target

D. Boral Capital analyst Jason Kolbert maintains Tevogen Bio Holdings (NASDAQ:TVGN) with a Buy an

benzinga.com
Tevogen Bio Issues Letter to Stockholders Highlighting Rapid Growth, AI Expansion, And Capital Posit

Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today released a l

benzinga.com
Tevogen Bio To Receive $1M Grant To Advance AI-Driven Drug Discovery Platform, Part Of $10M Non-Dilu

Funds will support advancement of Tevogen.AI, the Company's artificial intelligence–driven drug